Ivantis Inc., developer of the Hydrus Microstent device designed to lower eye pressure for glaucoma patients, has closed a $25 million Series C financing round led by new investor RA Capital Management. The round also included new investor Mérieux Développement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
